For biopharma investors, the opportunity lies in understanding which science can translate into value and how companies plan to get there. Fierce JPM Week 2027 brings you into conversations with executives and dealmakers evaluating emerging therapies, pursuing acquisitions and preparing for the public markets.

Explore what larger biotech funding rounds mean for investors, what pharma’s pipeline needs signal for potential exits and what it takes to succeed beyond an IPO. From next-generation obesity therapies to cross-border licensing, hear how leaders are weighing clinical promise against commercial potential to inform your investment decisions.